Inovio Q1 net loss narrows to $30.5M; BLA for INO-3107 on track for H2 2024

INOVIO PHARMACEUTICALS, INC.

2024-Q1 EPS reported -$1.31

BLA submission for INO-3107 (recurrent respiratory papillomatosis) on track for H2 2024 under accelerated approval pathway.
Phase 3 trial of INO-3112 + LOQTORZI for HPV-related throat cancer advancing; FDA feedback received.
Net loss $30.5M ($1.31/sh) vs $40.6M ($1.89/sh) in Q1 2023; R&D expenses fell to $20.9M.
Cash & equivalents $105.6M at Mar 31, 2024; April offering raised net ~$33.2M; cash runway into Q3 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INOVIO PHARMACEUTICALS, INC. reported financial results for first quarter of 2024.

Period: first quarter of 2024
Result: reported results

Exact text from the filing

On May 13, 2024, Inovio Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

INOVIO PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-24-137228

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.